Expert guides on PDUFA dates, FDA advisory committees, clinical trials, and executable biotech research protocols.
The confirmed PDUFA dates and clinical readouts driving biotech stocks through the rest of Q3 2026 — five FDA decisions and a slate of Phase 2/3 topline data, each traceable to the trial record.
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
How risk-adjusted net present value (rNPV) values a clinical-stage pipeline, why probability of success drives everything, and how to use it without fooling yourself.
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
How to use quarterly 13F filings to see which funds are building or exiting biotech positions, what the data can and can't tell you, and the timing pitfalls to avoid.
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
A Refuse to File is the FDA declining to even review an application. Learn what triggers an RTF, how it differs from a Complete Response Letter, and what it signals.
A practical guide to mining ClinicalTrials.gov for investment signals — status changes, enrollment, endpoints, completion dates, and the red flags hidden in trial records.
Why enrollment pace, not the protocol, usually drives a trial's timeline, how to spot delays early, and what slow enrollment signals about a biotech's catalysts and cash.
A practical framework for screening biotech — combining cash, catalysts, pipeline quality, and valuation — and how natural-language screening speeds the hunt.
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
How upfront payments, milestones, and royalties work in biotech licensing and partnership deals, and why they're a key non-dilutive financing and validation signal.
PDUFA extensions delay an FDA decision by up to three months. Learn why they happen, whether they're bullish or bearish, and how to interpret them as an investor.
Rolling review lets sponsors submit application sections as they're completed instead of all at once. Here's how it works, who qualifies, and what it means for catalyst timing.
How AAV-based gene therapies deliver a working gene, the durability and manufacturing questions that define them, and the unique commercial model of one-time cures.
How blinding and randomization affect the reliability of clinical data, why open-label results carry more bias risk, and what investors should weigh when a trial reads out.
How patent expiry and loss of exclusivity reshape pharma revenue, the difference between small-molecule generics and biosimilars, and how investors model the cliff.
What a going concern qualification means, why it's common in clinical-stage biotech, and how investors should weigh it against the pipeline and catalyst timeline.
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
How to build and maintain a catalyst calendar for biotech investing — which events to track, where the dates come from, and why a stale calendar is worse than none.
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
A focused guide to the annual 10-K for biotech investors — risk factors, liquidity, pipeline disclosures, and the footnotes where the real story often hides.
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Why biotech stocks move violently on single catalysts, how to think about binary risk and position sizing, and the behavioral traps around make-or-break events.
Why clinical-stage biotechs dilute constantly, how at-the-market (ATM) offerings work, and how to assess financing risk before it hits the share count.
Why the primary endpoint determines a trial's success or failure, how secondary and exploratory endpoints fit in, and the traps investors fall into when a study 'misses.'
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
Discover how natural language screening lets biotech investors compile plain-English criteria into executable company screens instead of rebuilding spreadsheet filters.
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Learn what to look for in biotech quarterly earnings reports, from cash burn and pipeline updates to guidance changes and hidden signals that move stock prices.
Compare FDA Priority Review and Standard Review timelines, learn what triggers each designation, and understand how review type affects drug approval probability and stock prices.
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Learn how to interpret SEC Form 4 insider trading filings for biotech companies, identify meaningful insider buying patterns, and avoid common misinterpretations.
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
Learn how to calculate biotech cash runway, identify dilution risk, interpret burn rate trends, and use financial data to time your biotech investments.
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
Learn what a Complete Response Letter is, why the FDA issues CRLs, how companies respond, and what CRL outcomes mean for biotech stock prices and timelines.
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Learn which SEC filings matter most for biotech companies, what to look for in 10-K, 10-Q, 8-K, and S-1 filings, and how to extract actionable insights.
Explore how AI changes biotech due diligence when a natural-language thesis becomes an executable, evidence-gated research protocol.
From reading to research rule
Start with the assumption you want to test; BioSniper will compile the criteria and evidence checks rather than copy the article's conclusion.